Investival ShowcaseMonday, 17 November 2025 - GMT (Greenwich Mean Time, GMTZ)

The journey from groundbreaking scientific discovery to accessible patient treatment is fraught with challenges, requiring seamless collaboration between researchers, investors, industry leaders, and technology transfer professionals. This panel explores the critical success factors, common pitfalls, and innovative strategies that can accelerate the translation of promising research into therapies that genuinely transform patient outcomes and healthcare delivery

• Evaluating scientific discoveries for their commercial and clinical potential, including biomarker validation, target identification, and early proof-of-concept studies that de-risk the development pathway
• Exploring diverse funding mechanisms from (seed funding, Series A rounds etc), and strategic partnerships that sustain innovation through the lengthy development process
• Analysing successful models for academia-industry collaboration, the role of accelerators and incubators in bridging knowledge gaps, and how strategic alliances can overcome resource limitations while maintaining focus on patient-centric outcomes
• Pharma - Working with start-up companies and helping them de-risk, co-create and scale up their value proposition and supporting them in their commercialization

Successfully raising series A financing is cause for celebration in the current investment climate. However, for successful companies this will be the first of many successes and milestones. The next step once series A funding has been secured is instrumental in the long-term strategy of the company, CEOs should consider further funding rounds, capital markets and deal making when evaluating what comes next.

• What different growth and scaling routes look like in practice

• Further funding rounds, IPO, or acquisition?

• How to know which route is best for you

Regulatory complexity in life sciences M&A & investment isn’t just a legal hurdle—it’s a strategic factor that can make or break a deal. This panel will explore how investors, biotech leaders, and dealmakers should integrate regulatory foresight into their M&A strategy to unlock long-term value, avoid deal derailment, and ensure the post-acquisition phase is as seamless as possible. Industry experts will discuss the real commercial impact of regulatory risk, from shaping valuations as products pass through regulatory pathways, to navigating compliance pressures post-close

Key Discussion Points:

· How understanding regulatory risk can make or break deals

· Pre-completion strategy: how to set the deal up for success

· Beyond the close: turning compliance into a competitive advantage and avoiding reputational damage

• Evaluating the optimal timing for pharma partnerships as a post-Series B Biotech
• Identifying pharma partners based on strategic fit
• Exploring innovative partnership models
• How are Post Series B Biotech’s utilising deals with Pharma as an income stream?
• Balancing investor expectations and pharma deal making as a late growth stage biotech